The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bagheri‐Yarmand, R., Talukder, A. H., Wang, R., Vadlamudi, R. K., & Kumar, R. (2004) · Development · doi:10.1242/dev.01213 · Cited by 97
RetractedStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.786 · Cited by 2,639
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Proteomic analysis of post-translational modifications
Mann, M., & Jensen, O. N. (2003) · Nature Biotechnology · doi:10.1038/nbt0303-255 · Cited by 2,134
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“A relatively wide range of structures have been identified that are able to inhibit the activity of class 1, class 2 and class 4 HDAC”
Background
Cited by
Items 101–153 of 153
Zhao, L., Chen, C.-N., Hajji, N., Oliver, E., Cotroneo, E., Wharton, J., Wang, D., Li, M., McKinsey, T. A., Stenmark, K. R., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.103176 · Cited by 259
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.436 · Cited by 259
SET8 promotes epithelial–mesenchymal transition and confers TWIST dual transcriptional activities
Yang, F., Sun, L., Li, Q., Han, X., Lei, L., Zhang, H., & Shang, Y. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.364 · Cited by 258
Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707362200 · Cited by 257
Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027912 · Cited by 255
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 253
Self-citationCrosstalk between chromatin state and DNA damage response in cellular senescence and cancer.
Sulli, G., Di Micco, R., & di Fagagna, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3344 · Cited by 238
Guo, W., Shan, B., Klingsberg, R. C., Qin, X., & Lasky, J. A. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00128.2009 · Cited by 218
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0509363 · Cited by 186
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Cancers with wrong HATs: the impact of acetylation
Di Cerbo, V., & Schneider, R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els065 · Cited by 178
Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8033763 · Cited by 165
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
“Knockdown of HDAC8 decreases the level of mutant p53 protein and transcript SAHA is a potent inhibitor of HDAC1-4 and 6–9 (32–34) whereas NaB inhibits most class I–II HDACs except HDAC6 and 10 (35, 36).”
BackgroundInfluentialScuto, A., Kirschbaum, M., Kowolik, C., Kretzner, L., Juhasz, A., Atadja, P., Pullarkat, V., Bhatia, R., Forman, S., Yen, Y., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117762 · Cited by 141
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Xia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119
Griffith, D., Morgan, M. P., & Marmion, C. J. (2009) · Chemical Communications · doi:10.1039/b916715c · Cited by 109
Wu, R., Lu, Z., Cao, Z., & Zhang, Y. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111104p · Cited by 108
Konsoula, R., & Jung, M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.001 · Cited by 108
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
“HDACs are the targets of a family of compounds known as HDAC inhibitors (HDACi) (12).”
BackgroundKinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
Wagner, F. F., Zhang, Y.-L., Fass, D. M., Joseph, N., Gale, J. P., Weïwer, M., McCarren, P., Fisher, S. L., Kaya, T., Zhao, W.-N., et al. (2015) · Chemical Science · doi:10.1039/c4sc02130d · Cited by 104
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Sigalotti, L., Fratta, E., Coral, S., & Maio, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.015 · Cited by 102
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
De Smaele, E., Di Marcotullio, L., Moretti, M., Pelloni, M., Occhione, M. A., Infante, P., Cucchi, D., Greco, A., Pietrosanti, L., Todorovic, J., et al. (2011) · Neoplasia · doi:10.1593/neo.101630 · Cited by 92
Histone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Histone Deacetylase Inhibitors Impair Antibacterial Defenses of Macrophages
Mombelli, M., Lugrin, J., Rubino, I., Chanson, A.-L., Giddey, M., Calandra, T., & Roger, T. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir553 · Cited by 89
Suh, H.-S., Choi, S., Khattar, P., Choi, N., & Lee, S. C. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9192-0 · Cited by 86
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86
Chang, Y.-W., Tseng, C.-F., Wang, M.-Y., Chang, W.-C., Lee, C.-C., Chen, L.-T., Hung, M.-C., & Su, J.-L. (2016) · Oncogene · doi:10.1038/onc.2015.214 · Cited by 82
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80
Cuadrado-Tejedor, M., Garcia-Barroso, C., Sanzhez-Arias, J., Mederos, S., Rabal, O., Ugarte, A., Franco, R., Pascual-Lucas, M., Segura, V., Perea, G., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0142-9 · Cited by 69
Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts
Diao, J.-S., Xia, W.-S., Yi, C.-G., Wang, Y.-M., Li, B., Xia, W., Liu, B., Guo, S.-Z., & Sun, X.-D. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1140-1 · Cited by 68
Nizzardo, M., Nardini, M., Ronchi, D., Salani, S., Donadoni, C., Fortunato, F., Colciago, G., Falcone, M., Simone, C., Riboldi, G., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.01.017 · Cited by 64
Uchida, H., Maruyama, T., Ono, M., Ohta, K., Kajitani, T., Masuda, H., Nagashima, T., Arase, T., Asada, H., & Yoshimura, Y. (2007) · Endocrinology · doi:10.1210/en.2006-0896 · Cited by 59
Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6
Lissanu Deribe, Y., Wild, P., Chandrashaker, A., Curak, J., Schmidt, M. H. H., Kalaidzidis, Y., Milutinovic, N., Kratchmarova, I., Buerkle, L., Fetchko, M. J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000576 · Cited by 60
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
“VEGF is overexpressed and its main receptor VEGFR-2 is up-regulated in many DTC [28].”
BackgroundLeiva, M., Moretti, S., Soilihi, H., Pallavicini, I., Peres, L., Mercurio, C., Dal Zuffo, R., Minucci, S., & de Thé, H. (2012) · Leukemia · doi:10.1038/leu.2012.39 · Cited by 58
Self-citationNishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H. P., & Taguchi, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.05.026 · Cited by 58
Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800461 · Cited by 51
A distal regulatory region of a class I human histone deacetylase
Werbeck, N. D., Shukla, V. K., Kunze, M. B. A., Yalinca, H., Pritchard, R. B., Siemons, L., Mondal, S., Greenwood, S. O. R., Kirkpatrick, J., Marson, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17610-w · Cited by 40
Chambliss, A. B., Wu, P., Chen, W., Sun, S. X., & Wirtz, D. (2013) · The FASEB Journal · doi:10.1096/fj.12-227108 · Cited by 34
“A reversal of hypoacetylation, by way of HDAC inhibition, could be an effective treatment option for cancer patients (10, 11).”
BackgroundParallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization
Kattar, S. D., Surdi, L. M., Zabierek, A., Methot, J. L., Middleton, R. E., Hughes, B., Szewczak, A. A., Dahlberg, W. K., Kral, A. M., Ozerova, N., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.083 · Cited by 29
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0629 · Cited by 27
“Additionally, valproic acid binds to serum proteins (up to 90% of the absorbed drug) and exhibits low potency (7).”
BackgroundKonsoula, Z., Cao, H., Velena, A., & Jung, M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.057 · Cited by 27
Starkova, J., Madzo, J., Cario, G., Kalina, T., Ford, A., Zaliova, M., Hrusak, O., & Trka, J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2569 · Cited by 24
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
“This starting material was reacted with 4-ethyl-2,3-dioxo-1-piperazine, cyclo-L-prolylglycine, 1-methylpiperazine-2,5-dione, 1-methyl-piperazin-2-one, tert-butyl 3-oxopiperazine-1-carboxylate and 1-ethylpiperazine in the presence of sodium hydride (NaH) to yield the condensation products 6a, 7a, 8a, 9a, 10a and 11a, w…”
BackgroundMethodInfluentialRamos, T. L., Sánchez-Abarca, L. I., Redondo, A., Hernández-Hernández, Á., Almeida, A. M., Puig, N., Rodríguez, C., Ortega, R., Preciado, S., Rico, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15969 · Cited by 13
“HDAC8 is a class I HDAC involved in various diseases, including cancer [11, 12].”
BackgroundA novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma
Choi, S. A., Kwak, P. A., Park, C.-K., Wang, K.-C., Phi, J. H., Lee, J. Y., Lee, C. S., Lee, J.-H., & Kim, S.-K. (2017) · Oncotarget · doi:10.18632/oncotarget.13265 · Cited by 13
Neal, A. S., Nunez, M., Lai, T., Tosevska, A., Morselli, M., Amneus, M., Zakhour, M., Moatamed, N. A., Pellegrini, M., & Memarzadeh, S. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00175-w · Cited by 11
Metadata
- Authors
- Minucci, S., & Pelicci, P. G.
- Venue
- Nature Reviews Cancer
- Published
- 2006-01-01
- Volume
- 6
- Issue
- 1
- Pages
- 38-51
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2099803844
- Cited by
- 2,200
- References
- 137
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.